Mounjaro Singapore (2026): HSA Approval, Eligibility, Cost, and What Patients Should Know

Weight management in Singapore has undergone a significant shift in recent years. Beyond lifestyle programmes, gym memberships, and commercial slimming centres, there is growing attention on medically supervised treatments for obesity and metabolic disease.

In Singapore, “Mounjaro” refers to tirzepatide, a prescription-only injectable medication approved by the Health Sciences Authority for the treatment of type 2 diabetes and chronic weight management in eligible adults under medical supervision.

This article provides an evidence-based overview of:

• What Mounjaro (tirzepatide) is
• Its approval status in Singapore
• Eligibility criteria under local guidelines
• Known risks and contraindication
• Estimated cost considerations
• Availability in 2026

This information is intended for public education.

What is Mounjaro?

Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication developed by Eli Lilly. 

Tirzepatide works by targeting two hormone receptors:

• GLP-1 (glucagon-like peptide-1)
• GIP (glucose-dependent insulinotropic polypeptide)

Earlier medications such as semaglutide primarily act on the GLP 1 receptor pathway. Tirzepatide’s dual receptor activity is believed to enhance blood sugar regulation and appetite control.

In large international clinical trials involving patients with obesity or overweight with medical comorbidities, participants receiving tirzepatide experienced significant weight loss over approximately 72 weeks when combined with lifestyle intervention. Individual results varied depending on dosage and adherence to diet and exercise recommendations.

Is Mounjaro Approved in Singapore?

Yes. Tirzepatide is approved in Singapore by the Health Sciences Authority (HSA).

Approval timeline in Singapore:

• March 2023 – Approved for use in adults with type 2 diabetes as an adjunct to diet and exercise
• June 2025 – Approval extended for chronic weight management in eligible adults

This means tirzepatide may be prescribed in Singapore for both: 

1. Type 2 diabetes mellitus
2. Chronic weight management in selected individuals

All prescribing must comply with HSA regulations and professional medical guidelines.

Who is Eligible for Tirzepatide for Weight Management in Singapore?

Under current approval guidelines, tirzepatide may be considered for adults who meet the following criteria:

• Body Mass Index (BMI) ≥ 30, or
• BMI ≥ 27 with at least one weight-related medical condition such as:
• • Hypertension
  • Type 2 diabetes
  • Dyslipidaemia (high cholesterol)
  • Obstructive sleep apnoea
  • Cardiovascular risk factors

Eligibility does not automatically guarantee prescription. A licensed doctor must assess:

• Medical history
• Current medications
• Cardiometabolic risk profile
• Potential contraindications
• Suitability for long-term therapy

Is Mounjaro Legal in Singapore?

Yes – but it is classified as a Prescription-Only Medicine (POM).

This means:

• It cannot be purchased over the counter.
• It cannot be legally imported for personal use without proper approval.
• It must be prescribed and dispensed under medical supervision.

Doctors are required to evaluate whether the medication is clinically appropriate before initiating treatment. 

How Does Tirzepatide Work for Weight Loss?

Tirzepatide influences appetite regulation and glucose metabolism through its effects on GLP-1 and GIP receptors. 

In practical terms, patients may experience:

• Reduced appetite
• Earlier satiety (feeling full sooner)
• Improved blood sugar stability
• Reduced caloric intake

Weight reduction typically occurs gradually over months rather than weeks. Dose escalation is usually required to improve tolerability and minimise gastrointestinal side effects.

It is important to note that medication effectiveness is maximised when combined with:

• Nutritional guidance
• Physical activity
• Behavioural modification

How Much Does Mounjaro Cost in Singapore (2026)?

Costs vary depending on dosage, prescribing clinic, and follow-up structure.

In 2026, reported monthly costs for tirzepatide treatment in Singapore generally fall within the range of:

• Approximately SGD 1,000 to SGD 1,300 per month at maintenance doses

Introductory doses may be lower during titration phases.

Because obesity is considered a chronic condition, treatment may be long term. Patients should understand the financial implications before initiating therapy.

Medication costs may change over time depending on supply, regulatory developments, and manufacturer pricing.

What Happens If Treatment is Stopped?

Clinical studies and real-world observations suggest that discontinuation of weight management medications may result in gradual weight regain, particularly if lifestyle measures are not sustained.

For this reason, doctors typically discuss:

• Long-term weight maintenance strategy
• Lifestyle sustainability
• Ongoing monitoring
• Exit plans if medication is discontinued

Tirzepatide is not considered a short-term cosmetic solution but part of a structured medical plan when used appropriately.

Who Should Not Use Tirzepatide?

Tirzepatide is not suitable for all individuals.

Based on regulatory guidance and prescribing information, doctors generally avoid use in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
• Severe gastrointestinal disease such as gastroparesis
• Previous pancreatitis (case-dependent evaluation required)
• Type 1 diabetes
• Pregnancy or breastfeeding

Careful screening is essential before initiation.

Common Side Effects

As with other medications in its class, common side effects may include:

• Nausea 
• Vomiting
• Diarrhoea
• Constipation
• Reduced appetite

These effects are often dose-dependent and may improve over time. Dose escalation schedules are typically designed to improve tolerability.

Severe or persistent symptoms require medical evaluation.

Availability in Singapore (2026 Update)

Although approved, availability can fluctuate due to global demand and manufacturing supply.

Tirzepatide is produced by Eli Lilly, and international demand may affect supply chains in different countries.

In Singapore, access may vary across:

• Public hospitals
• Private specialist clinics
• Licensed medical providers

Patients may encounter waiting periods depending on inventory levels.

Is Mounjaro the Same as Zepbound?

Internationally, tirzepatide is marketed under different brand names for different indications.

• Mounjaro is commonly associated with diabetes treatment.
• Zepbound (in some countries) is indicated for weight management.

Both contain tirzepatide as the active ingredient, but branding and regulatory labelling differ across markets.

In Singapore, Mounjaro is approved by the HSA for both diabetes treatment and weight management. Zepbound is not available in Singapore.

Mounjaro vs Other GLP 1 Medication in Singapore

Other weight loss medication used in metabolic management include semaglutide-based treatments.

Tirzepatide differs mechanistically due to its dual GLP-1 and GIP receptor activity.

Clinical comparisons across studies suggest meaningful weight reduction with both classes when combined with lifestyle modification. The most appropriate medication depends on:

• Individual risk factors
• Side effect tolerance
• Medical history
• Doctor assessment

No medication is universally superior for every patient.

The Role of Lifestyle in Long-Term Success

While medications can assist in appetite regulation and metabolic improvement, long-term success depends on behavioural and environmental factors.

Evidence consistently shows that sustained weight management requires:

• Dietary structure
• Physical activity
• Sleep optimisation
• Stress management
• Regular medical monitoring

Weight loss medication should be viewed as an adjunct to comprehensive care rather than a replacement for foundational health habits.

Regulatory Notice

This article is intended for public education and general information only. It does not constitute medical advice, diagnosis, or treatment recommendation. Tirzepatide is a prescription-only medicine in Singapore. Suitability, availability, and prescribing decisions are determined solely by a licensed medical practitioner in accordance with regulations set by the Health Sciences Authority.

Conclusion

Interest in Mounjaro Singapore reflects a broader shift toward medically supervised approaches to metabolic health and obesity management.

Tirzepatide represents a significant development in this field, with regulatory approval in Singapore for both type 2 diabetes and chronic weight management in eligible individuals.

However, it remains a prescription-only therapy requiring careful medical evaluation, long-term planning, and lifestyle integration. Individuals considering weight management treatment should consult a qualified healthcare professional to determine the most appropriate and safe approach based on their personal health profile.